It was recently reported that in NSCLC patients with brain metastases and certain EGFR mutations, a relatively high intracranial remission rate and prolonged survival can be achieved by treatment with small molecules EGFR tyrosine kinase inhibitors (EGFR-TKIs) [7,8]. Here, EGFR is linked to non-small cell lung carcinoma.